Literature DB >> 24816265

Post-transcriptional regulation in osteoblasts using localized delivery of miR-29a inhibitor from nanofibers to enhance extracellular matrix deposition.

Eric N James1, Anne M Delany2, Lakshmi S Nair3.   

Abstract

MicroRNAs are important post-transcriptional regulators of skeletal biology, and miRNA-based therapeutics have the potential to aid bone repair. However, efficient tools for delivering miRNA mimics or inhibitors to specific target tissues are limited. Polymeric nanofibers closely mimic natural extracellular matrix (ECM) morphology, and are attractive candidates for supporting delivery of cells and bone-anabolic reagents. It is hypothesized that gelatin nanofibers could be used for the localized transient delivery of miRNA-based therapeutics, using miR-29a inhibitor as a prototype to increase ECM deposition. miR-29 family members are negative regulators of ECM synthesis, targeting the mRNAs of selected collagens and osteonectin/SPARC. Inhibiting miR-29 activity may therefore increase ECM production by cells. miR-29a inhibitor-loaded gelatin nanofibers, prepared by electrospinning, demonstrated continuous release of miRNA inhibitor over 72h. Pre-osteoblastic murine MC3T3-E1 cell line seeded on miR-29a inhibitor-loaded nanofibers synthesized more osteonectin, indicating efficient inhibitor delivery. These cells also displayed increased Igf1 and Tgfb1 mRNA. Moreover, primary bone marrow stromal cells from transgenic pOBCol3.6cyan reporter mice, grown on miR-29a inhibitor scaffolds, displayed increased col3.6 cyan expression as well as collagen production. This study demonstrates that ECM mimicking nanostructured scaffolds, in conjunction with bioactive miRNA-based therapeutics, may serve as a novel platform for developing biologically active localized cell delivery systems. Published by Elsevier Ltd.

Entities:  

Keywords:  Bone; Extracellular matrix; Nanofibers; Osteonectin; microRNA

Mesh:

Substances:

Year:  2014        PMID: 24816265      PMCID: PMC4114157          DOI: 10.1016/j.actbio.2014.04.026

Source DB:  PubMed          Journal:  Acta Biomater        ISSN: 1742-7061            Impact factor:   8.947


  41 in total

1.  The effect of controlled release of PDGF-BB from heparin-conjugated electrospun PCL/gelatin scaffolds on cellular bioactivity and infiltration.

Authors:  Jongman Lee; James J Yoo; Anthony Atala; Sang Jin Lee
Journal:  Biomaterials       Date:  2012-07-06       Impact factor: 12.479

2.  A delivery system targeting bone formation surfaces to facilitate RNAi-based anabolic therapy.

Authors:  Ge Zhang; Baosheng Guo; Heng Wu; Tao Tang; Bao-Ting Zhang; Lizhen Zheng; Yixin He; Zhijun Yang; Xiaohua Pan; Heelum Chow; Kinwah To; Yaping Li; Dahu Li; Xinluan Wang; Yixiang Wang; Kwongman Lee; Zhibo Hou; Nan Dong; Gang Li; Kwoksui Leung; Leungkim Hung; Fuchu He; Lingqiang Zhang; Ling Qin
Journal:  Nat Med       Date:  2012-01-29       Impact factor: 53.440

3.  TGF-β3 immobilized PLGA-gelatin/chondroitin sulfate/hyaluronic acid hybrid scaffold for cartilage regeneration.

Authors:  Hongbin Fan; Huiren Tao; Yingnan Wu; Yunyu Hu; Yongnian Yan; Zhuojin Luo
Journal:  J Biomed Mater Res A       Date:  2010-09-24       Impact factor: 4.396

4.  miR-29 suppression of osteonectin in osteoblasts: regulation during differentiation and by canonical Wnt signaling.

Authors:  Kristina Kapinas; Catherine B Kessler; Anne M Delany
Journal:  J Cell Biochem       Date:  2009-09-01       Impact factor: 4.429

Review 5.  Bioengineered nanoparticles for siRNA delivery.

Authors:  Kristen L Kozielski; Stephany Y Tzeng; Jordan J Green
Journal:  Wiley Interdiscip Rev Nanomed Nanobiotechnol       Date:  2013-07-02

6.  RNA interference by nanofiber-based siRNA delivery system.

Authors:  Haoqing Cao; Xu Jiang; Chou Chai; Sing Yian Chew
Journal:  J Control Release       Date:  2010-02-06       Impact factor: 9.776

Review 7.  Cartilage and bone extracellular matrix.

Authors:  Chiara Gentili; Ranieri Cancedda
Journal:  Curr Pharm Des       Date:  2009       Impact factor: 3.116

8.  Distribution of noncollagenous proteins in the matrix of adult human bone: evidence of anatomic and functional heterogeneity.

Authors:  R T Ingram; B L Clarke; L W Fisher; L A Fitzpatrick
Journal:  J Bone Miner Res       Date:  1993-09       Impact factor: 6.741

Review 9.  IGF-1 and bone: New discoveries from mouse models.

Authors:  Shoshana Yakar; Hayden-William Courtland; David Clemmons
Journal:  J Bone Miner Res       Date:  2010-12       Impact factor: 6.741

Review 10.  MicroRNA biogenesis and regulation of bone remodeling.

Authors:  Kristina Kapinas; Anne M Delany
Journal:  Arthritis Res Ther       Date:  2011-05-27       Impact factor: 5.156

View more
  13 in total

Review 1.  Electrospun-Fibrous-Architecture-Mediated Non-Viral Gene Therapy Drug Delivery in Regenerative Medicine.

Authors:  Elena Cojocaru; Jana Ghitman; Raluca Stan
Journal:  Polymers (Basel)       Date:  2022-06-29       Impact factor: 4.967

2.  Silk Biomaterials-Mediated miRNA Functionalized Orthopedic Devices.

Authors:  Eric N James; Emily Van Doren; Chunmei Li; David L Kaplan
Journal:  Tissue Eng Part A       Date:  2018-08-22       Impact factor: 3.845

3.  MicroRNAs and Bone Regeneration.

Authors:  Tomoyuki Nakasa; Masaaki Yoshizuka; Muhammad Andry Usman; Elhussein Elbadry Mahmoud; Mitsuo Ochi
Journal:  Curr Genomics       Date:  2015-12       Impact factor: 2.236

4.  miR-29a Participated in Nacre Formation and Immune Response by Targeting Y2R in Pinctada martensii.

Authors:  Rongrong Tian; Zhe Zheng; Ronglian Huang; Yu Jiao; Xiaodong Du
Journal:  Int J Mol Sci       Date:  2015-12-10       Impact factor: 5.923

5.  miR-34a promotes bone regeneration in irradiated bone defects by enhancing osteoblastic differentiation of mesenchymal stromal cells in rats.

Authors:  Huan Liu; Yan Dong; Xiaoke Feng; Liya Li; Yang Jiao; Shizhu Bai; Zhihong Feng; Hao Yu; Xuejian Li; Yimin Zhao
Journal:  Stem Cell Res Ther       Date:  2019-06-18       Impact factor: 6.832

Review 6.  Small non-coding RNAs-based bone regulation and targeting therapeutic strategies.

Authors:  Ying Yang; Sijie Fang
Journal:  Mol Cell Endocrinol       Date:  2016-11-23       Impact factor: 4.102

7.  Chronic miR-29 antagonism promotes favorable plaque remodeling in atherosclerotic mice.

Authors:  Victoria Ulrich; Noemi Rotllan; Elisa Araldi; Amelia Luciano; Philipp Skroblin; Mélanie Abonnenc; Paola Perrotta; Xiaoke Yin; Ashley Bauer; Kristen L Leslie; Pei Zhang; Binod Aryal; Rusty L Montgomery; Thomas Thum; Kathleen Martin; Yajaira Suarez; Manuel Mayr; Carlos Fernandez-Hernando; William C Sessa
Journal:  EMBO Mol Med       Date:  2016-06-01       Impact factor: 12.137

8.  Next generation bone tissue engineering: non-viral miR-133a inhibition using collagen-nanohydroxyapatite scaffolds rapidly enhances osteogenesis.

Authors:  Irene Mencía Castaño; Caroline M Curtin; Garry P Duffy; Fergal J O'Brien
Journal:  Sci Rep       Date:  2016-06-14       Impact factor: 4.379

9.  Designing Acellular Injectable Biomaterial Therapeutics for Treating Myocardial Infarction and Peripheral Artery Disease.

Authors:  Melissa J Hernandez; Karen L Christman
Journal:  JACC Basic Transl Sci       Date:  2017-04-24

10.  miR‑185‑5p inhibits F‑actin polymerization and reverses epithelial mesenchymal transition of human breast cancer cells by modulating RAGE.

Authors:  Chonggao Yin; Guoxin Zhang; Ruimei Sun; Xinting Pan; Xuewen Wang; Hongli Li; Yunbo Sun
Journal:  Mol Med Rep       Date:  2018-07-16       Impact factor: 2.952

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.